SWX:COPN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. More Details


Snowflake Analysis

Exceptional growth potential and fair value.


Similar Companies

Share Price & News

How has Cosmo Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: COPN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: COPN's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-1.6%

COPN

-0.6%

CH Pharmaceuticals

-1.3%

CH Market


1 Year Return

13.7%

COPN

-6.5%

CH Pharmaceuticals

-1.3%

CH Market

Return vs Industry: COPN exceeded the Swiss Pharmaceuticals industry which returned -6.5% over the past year.

Return vs Market: COPN exceeded the Swiss Market which returned -1.3% over the past year.


Shareholder returns

COPNIndustryMarket
7 Day-1.6%-0.6%-1.3%
30 Day5.3%-2.2%0.4%
90 Day-4.1%-2.1%1.9%
1 Year13.7%13.7%-3.3%-6.5%2.2%-1.3%
3 Year-37.0%-37.0%30.0%11.2%17.6%5.1%
5 Year-45.8%-46.9%30.2%4.6%41.9%18.4%

Long-Term Price Volatility Vs. Market

How volatile is Cosmo Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cosmo Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: COPN (CHF83.6) is trading below our estimate of fair value (CHF406)

Significantly Below Fair Value: COPN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: COPN is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.

PE vs Market: COPN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate COPN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: COPN is good value based on its PB Ratio (2.8x) compared to the CH Pharmaceuticals industry average (3.3x).


Next Steps

Future Growth

How is Cosmo Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

80.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COPN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.2%).

Earnings vs Market: COPN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: COPN's is expected to become profitable in the next 3 years.

Revenue vs Market: COPN's revenue (42.6% per year) is forecast to grow faster than the Swiss market (4.8% per year).

High Growth Revenue: COPN's revenue (42.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COPN's Return on Equity is forecast to be high in 3 years time (23%)


Next Steps

Past Performance

How has Cosmo Pharmaceuticals performed over the past 5 years?

-80.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COPN is currently unprofitable.

Growing Profit Margin: COPN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: COPN is unprofitable, and losses have increased over the past 5 years at a rate of 80.7% per year.

Accelerating Growth: Unable to compare COPN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: COPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.5%).


Return on Equity

High ROE: COPN has a negative Return on Equity (-1.66%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cosmo Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: COPN's short term assets (€291.9M) exceed its short term liabilities (€17.2M).

Long Term Liabilities: COPN's short term assets (€291.9M) exceed its long term liabilities (€174.0M).


Debt to Equity History and Analysis

Debt Level: COPN's debt to equity ratio (40.1%) is considered high.

Reducing Debt: COPN's debt to equity ratio has increased from 0.7% to 40.1% over the past 5 years.

Debt Coverage: COPN's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: COPN is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Cosmo Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.02%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate COPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate COPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if COPN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if COPN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: COPN is not paying a notable dividend for the Swiss market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of COPN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Alessandro Della Chà (57 yo)

6.75yrs

Tenure

€3,323,861

Compensation

Mr. Alessandro E. Della Chà, LL.M, has been the Chief Executive Officer of Cosmo Pharmaceuticals N.V. (formerly Cosmo Pharmaceuticals S.p.A) since March 27, 2014 and also has been its Executive Director si...


CEO Compensation Analysis

Compensation vs Market: Alessandro's total compensation ($USD4.03M) is above average for companies of similar size in the Swiss market ($USD1.20M).

Compensation vs Earnings: Alessandro's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mauro Ajani
Founder & Executive Chairman6.92yrs€3.11mno data
Alessandro Della Chà
CEO & Executive Director6.75yrs€3.32mno data
Giuseppe Cipriano
Chief Operating Officer19.92yrsno datano data
Niall Donnelly
CFO & Head of Investor Relations4.5yrsno datano data
Davide Malavasi
Qualified Person & Technical Director9.25yrsno datano data
Stefano Selva
Chief Scientific Officer0.17yrno datano data
Blake Boland
Chief Sales Officer4.17yrsno datano data
Massimo Pedrani
Head of Generics Business Developmentno datano datano data
Roberto Villa
Chief Manufacturing Officerno datano datano data
Marco Lecchi
Head of Internal Audit19.75yrsno datano data
Luisa Bartorelli
Chief Patent Counsel6.83yrsno datano data
Thomas Joyce
Chief of US Operations4.42yrsno datano data

6.8yrs

Average Tenure

60yo

Average Age

Experienced Management: COPN's management team is seasoned and experienced (6.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mauro Ajani
Founder & Executive Chairman6.92yrs€3.11mno data
Alessandro Della Chà
CEO & Executive Director6.75yrs€3.32mno data
Dieter Enkelmann
Non-Executive Director14.92yrs€230.59kno data
William Sandborn
Member of Scientific Advisory Boardno datano datano data
Hans Tanner
Non-Executive Director14.92yrs€1.69mno data
Geert D'Haens
Member of Scientific Advisory Boardno datano datano data
Silvio Danese
Member of Scientific Advisory Boardno datano datano data
Maria Roncarolo
Non-Executive Director8.67yrs€230.59kno data
Ralf Kiesslich
Member of Scientific Advisory Boardno datano datano data
Alessandro Repici
Member of Scientific Advisory Boardno datano datano data
Robert Steffen
Member of Scientific Advisory Boardno datano datano data
Kevin Donovan
Non-Executive Director4.75yrs€230.59kno data

11.8yrs

Average Tenure

63yo

Average Age

Experienced Board: COPN's board of directors are seasoned and experienced ( 11.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cosmo Pharmaceuticals N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cosmo Pharmaceuticals N.V.
  • Ticker: COPN
  • Exchange: SWX
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF1.196b
  • Shares outstanding: 14.46m
  • Website: https://www.cosmopharma.com

Number of Employees


Location

  • Cosmo Pharmaceuticals N.V.
  • Riverside II
  • Sir John Rogerson’s Quay
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
COPNSWX (SIX Swiss Exchange)YesNew Common SharesCHCHFMar 2007
C43DB (Deutsche Boerse AG)YesNew Common SharesDEEURMar 2007
CMOP.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDMar 2007
COPNZBATS-CHIXE (BATS 'Chi-X Europe')YesNew Common SharesGBCHFMar 2007
0RGILSE (London Stock Exchange)YesNew Common SharesGBCHFMar 2007

Biography

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. The company offers Lialda/Mezavant/Mesavancol ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 18:03
End of Day Share Price2020/12/04 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.